



IN THE UNITED STATES PATENT  
AND TRADEMARK OFFICE

Serial No. : 10/535,000

Applicants : Masakazu HATANO et al.

Filed : May 16, 2005

For : THERAPEUTIC AGENT FOR  
GLAUCOMA COMPRISING Rho  
KINASE INHIBITOR AND  
β-BLOCKER

Art Unit : 1617

Examiner : Gigi Georgiana HUANG

Docket No. : 05318/HG

Confirm No. : 1033

Customer No.: 01933

**INFORMATION DISCLOSURE STATEMENT  
FILED CONCOMITANTLY WITH RCE**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**MAIL STOP RCE**

S I R :

Submitted herewith are the following:

A. Copies of the following documents relating to a demand  
for a Trial for Invalidation in the corresponding Japanese Patent  
4314433 (Japanese Patent Application No. 2000-564663) :

Document (1) : Demand for Trial and a partial English-  
language translation thereof (including  
a DECLARATION of accuracy of translation of  
Gihei Nakamura dated November 22, 2010);

Express Mail Mailing Label  
No.: EM 501 329 131 US  
Date of Deposit: January 14, 2011

I hereby certify that this paper is  
being deposited with the United States  
Postal Service "Express Mail Post  
Office to Addressee" service under  
37 CFR 1.10 with sufficient postage  
on the date indicated above and is  
addressed to:  
MAIL STOP RCE  
Commissioner for Patents,  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dorothy DeFrancesco

In the event that this Paper is late  
filed, and the necessary petition  
for extension of time is not filed  
concurrently herewith, please consider  
this as a Petition for the requisite  
extension of time, and to the extent  
not tendered by payment herewith,  
authorization is hereby given to charge  
the extension fee, or any other fee  
required in connection with this  
Paper to Account No. 06-1378.

Document (2) : Exhibit No. 1 in said Trial for Invalidation, namely, Japanese National Patent Publication No. 7-508030 and the corresponding published International Application, namely WO 93/23082;

Document (3) : Exhibit No. 3 in said Trial for Invalidation, namely Japanese national Patent Publication No. 2001-509780 (the corresponding published International Application, namely WO 97/23222 is of record in the above-identified application);

Document (4) : Exhibit No. 5 in said Trial for Invalidation, namely "Gekkan Ganka Shinryo Practice (Practical Ophthalmology)," 42. Tenganyaku no Tsukaikata (How to Use Eye Drops), 1999, pp. 52-53 and a partial English-language translation thereof (including a DECLARATION of accuracy of translation of Gihei Nakamura dated October 28, 2010);

Document (5) : Exhibit No. 6 in said Trial for Invalidation, namely "Gekkan Yakuji (The Pharmaceuticals Monthly)," 1996, Vol. 38, No. 9, pp. 2311-2331 and a partial English-language translation thereof (including a

DECLARATION of accuracy of translation of  
Gihei Nakamura) dated October 28, 2010;

Document (6) : Exhibit No. 12 in said Trial for  
Invalidation, namely Am. J. Physiol. Cell  
Physiol., 278, C57-C65, (2000);

Document (7) : Exhibit No. 16 in said Trial for  
Invalidation, namely the Notice of Grounds  
of Rejection drafted on August 27, 2007 in  
connection with Japanese Patent Application  
No. 2000-564663 and a partial English-  
language translation thereof (including a  
DECLARATION of accuracy of translation of  
Gihei Nakamura dated October 28, 2010); and

Document (8) : Board Decision for said Trial for  
Invalidation and a partial English-language  
translation thereof (including a DECLARATION  
of accuracy of translation of Gihei Nakamura  
dated November 22, 2010).

B. An IDS form identifying the aforesaid documents.

The applicants have informed the undersigned that although  
there was a demand for a Trial for Invalidation regarding the

corresponding Japanese patent, the patent was judged to be valid at the conclusion of the proceedings.

As shown hereinbelow, the following Exhibits listed in the enclosed BOARD DECISION are identified in the following INFORMATION DISCLOSURE STATEMENTS (IDS) which are of record in the above-identified application:

<u>Exhibit No.</u>	<u>Document</u>	<u>Date of IDS</u>
2	WO 00/09162	June 27, 2005
4	<u>Nature</u> , (1997), Vol. 389, pp. 990-994	June 27, 2005
6	<u>Expert Opinion of Emerging Drugs</u> , (2002), Vol. 7, No. 1, pp. 141-163	August 16, 2007
7	<u>Drugs</u> , (2000), Vol. 59, No. 3, pp. 411-434	June 27, 2005
9	<u>Invest. Ophthalmol. Vis. Sci.</u> , (2001), Vol. 42, No. 1, pp. 137-144	June 27, 2005
10	<u>Invest. Ophthalmol. Vis. Sci.</u> , (2001), Vol. 42, No. 5, pp. 1029-1037	June 27, 2005

It is respectfully requested that an initialed copy of the enclosed IDS Form be returned to indicate that all the documents listed therein have been considered and made of record.

Respectfully submitted,



RICHARD S. BARTH  
REG. NO. 28,180

HOLTZ, HOLTZ, GOODMAN & CHICK PC  
220 FIFTH AVENUE, 16th FLOOR  
NEW YORK, NEW YORK 10001-7708  
Tel. Nos. (212) 319-4900  
             (212) 319-4551/Ext. 219  
Fax No. (212) 319-5101  
E-Mail Address: RBARTH@HHPATENT.COM  
RSB/ddf